基本情報
- 所属
- 自治医科大学 附属さいたま医療センター心血管治療部 教授 (心血管治療部長)(兼任)附属さいたま医療センター循環器内科 教授
- 学位
- 医学博士(自治医科大学)
- 研究者番号
- 20773310
- J-GLOBAL ID
- 201501004058346154
- Researcher ID
- AAK-4564-2020
- researchmap会員ID
- B000247981
研究キーワード
2研究分野
1学歴
1-
- 1999年3月
受賞
21論文
303-
Journal of cardiology cases 19(6) 200-203 2019年6月 査読有り
-
International heart journal 60(3) 560-568 2019年5月30日 査読有りRight ventricular infarction (RVI) is a complication following inferior ST-elevation myocardial infarction (STEMI). The aim of the present study was to investigate the clinical outcomes of RVI in the contemporary primary percutaneous coronary intervention (PCI) era. The primary endpoint was in-hospital death, and the secondary endpoint was major adverse cardiac events (MACE), defined as the composite of cardiovascular death, re-hospitalization for heart failure, and non-fatal acute myocardial infarction (AMI). Event-free survival curves for MACE were constructed using the Kaplan-Meier method, and statistical differences between curves were assessed using the log-lank test. A total of 1354 patients with AMI were screened from January 2010 to December 2016. The final study population involved 315 patients with STEMI whose infarct related artery (IRA) was the right coronary artery (RCA). We categorized these 315 patients into the RVI group (n = 85) and the non-RVI group (n = 230). Median follow-up duration was 358 (IQR: 208-987) days. In-hospital deaths were more frequently observed in the RVI group (9.4%) than in the non-RVI group (3.0%) (P = 0.018). However, the incidence of MACE was not different between the groups (P = 0.537). In conclusion, in-hospital clinical outcomes were poorer in the RVI group than in the non-RVI group. However, mid-term MACE was not different between the two groups, suggesting the importance of aggressive acute treatment for STEMI patients with RVI.
-
Heart and vessels 2019年5月 査読有り
-
Journal of rural medicine : JRM 14(1) 116-119 2019年5月 査読有り
-
Cardiovascular revascularization medicine : including molecular interventions 2019年5月 査読有り
-
Cardiovascular Intervention and Therapeutics 34(2) 182-183 2019年4月15日
-
Circulation journal : official journal of the Japanese Circulation Society 83(5) 1039-1046 2019年4月 査読有り
-
BMC cardiovascular disorders 19(1) 41-41 2019年2月19日 査読有りBACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease characterized by fibrofatty replacement and ventricular arrhythmias. ARVC is believed to be a disease of the young, with most cases being diagnosed before the age of 40 years. We report here a case of newly diagnosed ARVC in an octogenarian associated with a pathogenic variant in the plakophilin 2 gene (PKP2). CASE PRESENTATION: An 80-year-old Japanese man was referred for sustained ventricular tachycardia. His baseline electrocardiogram showed negative T waves in V1-V4. Right ventriculography showed right ventricular aneurysm. Because this case met three major criteria, ARVC was diagnosed. He was successfully treated with radiofrequency ablation and oral amiodarone. Genetic analysis identified an insertion mutation in exon 8 of PKP2 (1725_1728dupGATG), which caused a frameshift and premature termination of translation (R577DfsX5). CONCLUSIONS: To the best of our knowledge, this is the first report of newly diagnosed ARVC in an octogenarian associated with a loss-of-function PKP2 pathogenic variant. Although the late clinical presentation of ARVC is rare, it should be included in the differential diagnosis when treating older patients with ventricular tachyarrhythmias.
-
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 93(3) 494-502 2019年2月 査読有り
-
Postepy w kardiologii interwencyjnej = Advances in interventional cardiology 15(4) 431-438 2019年 査読有りIntroduction: Transcatheter aortic valve implantation (TAVI) has grown to be an alternative treatment for severe symptomatic aortic valve stenosis (AS) in elderly patients. Although TAVI is a less invasive surgery than surgical aortic valve replacement, some patients may require prolonged hospitalization. Aim: To find the determinants of prolonged hospitalization in patients who underwent trans-femoral TAVI. Material and methods: A total of 94 AS patients who underwent trans-femoral TAVI were included as the final study population, and divided into the conventional hospitalization group (≤ 21 days) (n = 74) and prolonged hospitalization group (> 21 days) (n = 20). We compared clinical characteristics between the two groups, and multivariate logistic regression analysis was performed to find the determinants of prolonged hospitalization. Results: In multivariate logistic regression analysis, moderate or severe mitral regurgitation (OR = 4.49, 95% CI: 1.16-17.47, p = 0.03), taking statins or angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB) on admission (statins: OR = 0.13, 95% CI: 0.02-0.71, p = 0.02, ACE inhibitors/ARB: OR = 0.25, 95% CI: 0.06-0.96, p = 0.04), estimated glomerular filtration rate (eGFR) (per 15 ml/min/1.73 m2 incremental) (OR = 0.49, 95% CI: 0.26-0.90, p = 0.02) and current chopsticks user (OR = 0.05, 95% CI: 0.01-0.41, p < 0.01) were significantly associated with prolonged hospitalization. Conclusions: Moderate or severe mitral regurgitation was significantly associated with prolonged hospitalization, while current chopsticks user, eGFR (per 15 ml/min/1.73 m2 incremental), taking ACE inhibitors/ARB or statins before the procedure were inversely associated with prolonged hospitalization in patients who underwent trans-femoral TAVI.
-
International heart journal 60(1) 215-219 2019年1月 査読有り
-
International heart journal 60(1) 37-44 2019年1月 査読有り
-
International heart journal 59(6) 1237-1245 2018年11月 査読有り
-
Cardiovascular intervention and therapeutics 33(4) 338-344 2018年10月 査読有りIn-hospital outcomes of acute myocardial infarction (AMI) with cardiogenic shock (CS) were still not satisfactory even in the primary percutaneous coronary intervention (PCI) era. The aim of this study was to compare in-hospital outcomes of AMI with CS caused by right coronary artery (RCA) occlusion vs. left coronary artery (LCA) occlusion. Consecutive 894 AMI patients from January 2010 to March 2015 were screened for inclusion. A total of 114 AMI patients with CS were included as the final study population, and were divided into the RCA group (n = 56) and LCA group (n = 58). The patient characteristics were compared between the two groups. Multivariate logistic regression analysis was performed to show whether the RCA group was associated with better outcomes even after controlling confounding factors. In-hospital mortality was significantly lower in the RCA group (8.9%) than in the LCA group (46.6%) (P < 0.001). The RCA group (vs. the LCA group) was inversely associated with in-hospital death (OR 0.08, 95% CI 0.02-0.21, P < 0.001) after controlling covariates. Aspartate transaminase value (per 50 U/L incremental: OR 1.22, 95% CI 1.03-1.45, P = 0.02), aging (per 10-year-old incremental: OR 2.14, 95% CI 1.26-3.63, P = 0.01) and using VA-ECMO (OR 22.13, 95% CI 5.22-93.90, P < 0.001) were also significantly associated with in-hospital death. In conclusion, among AMI patients with CS, IRA of RCA was significantly associated with the better in-hospital outcome.
-
Journal of cardiology 72(3) 227-233 2018年9月 査読有り
-
Journal of thoracic disease 10(Suppl 26) S3176-S3181 2018年9月 査読有り
-
日本心血管インターベンション治療学会抄録集 27回 MO084-MO084 2018年8月 査読有り
-
Heart and Vessels 33(7) 713-721 2018年7月1日 査読有り
-
Cardiovascular revascularization medicine : including molecular interventions 19(5 Pt B) 607-612 2018年7月 査読有り
-
International heart journal 59(4) 766-771 2018年7月 査読有り
-
International heart journal 59(4) 887-890 2018年7月 査読有り
-
Heart and Vessels 33(5) 498-506 2018年5月1日 査読有り
-
International Heart Journal 59(3) 482-488 2018年5月1日 査読有り
-
Cardiovascular Revascularization Medicine 19(3) 286-291 2018年4月1日 査読有り
-
International heart journal 59(2) 451-454 2018年3月30日 査読有りA 32-year-old man with a history of bronchial asthma was referred for low back pain and bilateral femur pain. Vascular sonography revealed bilateral deep vein thrombosis (DVT) from the femoral veins to the popliteal veins. Computed tomography revealed hypoplasia of the inferior vena cava (IVC) and dilated lumbar veins, ascending lumbar veins, and azygos vein as collaterals. There was no evidence of malignant neoplasm. The results of the thrombophilia tests were within normal limits. Hypoplasia of the IVC is a rare cause of DVT. This anomaly should be considered as a cause of bilateral and proximal DVT, in particular, in young patients without major risk factors.
-
Heart and Vessels 33(3) 226-238 2018年3月1日 査読有り
-
Circulation: Cardiovascular Interventions 11(2) e005779 2018年2月1日 査読有り
-
Heart and Vessels 33(1) 25-32 2018年1月1日 査読有り
-
Heart and Vessels 33(1) 33-40 2018年1月1日 査読有り
-
Circulation Journal 82(4) 983-991 2018年 査読有り
-
International Heart Journal 59(1) 216-219 2018年 査読有り
-
International Heart Journal 59(2) 399-402 2018年 査読有り
-
International Heart Journal 59(2) 407-412 2018年 査読有り
-
Cardiovascular Revascularization Medicine 20(4) 347-350 2018年 査読有り
-
Cardiovascular Revascularization Medicine 20(2) 113-119 2018年 査読有り
-
JACC. Cardiovascular interventions 10(24) E227-E229 2017年12月 査読有り
-
HEART AND VESSELS 32(11) 1382-1389 2017年11月 査読有り
-
Journal of rural medicine : JRM 12(2) 149-152 2017年11月 査読有り<p>Acute symptomatic deep vein thrombosis (DVT) is usually managed by intravenous heparin and oral warfarin. Recently, direct oral anticoagulants (DOAC) have been introduced for the treatment of acute DVT. DOAC may be useful for very elderly patients who live in rural areas, where medical resources are limited. An 83-year-old woman presented to our clinic with left leg edema. Contrast enhanced computed tomography showed massive deep vein thrombosis in her left internal iliac vein. We diagnosed her with acute deep vein thrombosis. Since she refused to be hospitalized, we treated her with rivaroxaban as an outpatient. She had a good clinical course without hospitalization or an adverse event. DOAC may be useful for very elderly patients in rural areas.</p>
-
Cardiovascular Revascularization Medicine 18(6) 52-53 2017年9月1日 査読有り
-
International Heart Journal 58(5) 831-834 2017年9月1日 査読有り
-
Clinical case reports 5(6) 787-791 2017年6月 査読有り
-
Cardiovascular Revascularization Medicine 18(4) 295-298 2017年6月1日 査読有り
-
HEART AND VESSELS 32(5) 514-519 2017年5月 査読有り
MISC
33-
CIRCULATION 140 2019年11月
-
EUROPEAN HEART JOURNAL 36 1002-1002 2015年8月
-
JOURNAL OF CARDIAC FAILURE 20(10) S168-S168 2014年10月
-
EUROPEAN HEART JOURNAL 35 1083-1083 2014年9月
-
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 64(11) B121-B121 2014年9月
書籍等出版物
1共同研究・競争的資金等の研究課題
2-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2022年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2017年4月 - 2020年3月